Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). Findings from the Phase II single center study published today in JAMA Oncology.
Cancer testing company Freenome to lay off 100 employees
Freenome, a maker of blood-based cancer tests, will lay off more than 100 employees, or 20% of its workforce, a spokesperson for the company told
April 25, 2024